Exogenous Insulin Therapy Is Associated with the Risk of Advanced Colorectal Adenoma in Patients with Diabetes Mellitus
Digestive Diseases and Sciences · 2024
DOI: 10.1007/s10620-024-08350-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Digestive Diseases and Sciences, 2024. Verfasst von Robert Lam und 4 weiteren Autor:innen. Beteiligte Einrichtung: Section of Digestive Diseases, Yale School of Medicine, New Haven, CT, USA. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Insulin, Adenoma, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: CSRD VA, U.S. Department of Veterans Affairs.
Themen: Diabetes mellitus
Abstract (Originalsprache)
BACKGROUND/AIMS: Exogenous insulin therapy increases systemic exposure to insulin which may promote the development of colorectal neoplasia. We sought to evaluate the association between exogenous insulin therapy and the incidence of advanced adenoma in type 2 diabetes mellitus. METHODS: A retrospective cohort study was conducted from January 1, 2007, to January 1, 2018, in a regional health system serving the United States Philadelphia metropolitan area, Central New Jersey, and South Central Pennsylvania. Study patients consisted of a random sample of patients with type 2 diabetes mellitus aged 40-80 years who had undergone two rounds of colonoscopy examinations. The exposure was cumulative duration of insulin therapy (i.e., no use, 1-365 days and > 365 days). The outcome was time to incident advanced adenoma. RESULTS: Of the 975 eligible patients, 184 patients accumulated > 365 days of insulin therapy before the follow-up colonoscopy. The mean (standard deviation) duration between the two rounds of colonoscopy examination was 5.1 (2.9) years among the insulin users and 5.3 (3.9) years among non-users. Compared to no insulin exposure, receiving > 365 days of insulin therapy was associated with an increased incidence of advanced adenoma (adjusted hazard ratio [aHR] 4.84, 95% confidence interval [CI] 2.82-8.30), right-sided advanced adenoma (aHR 5.48, 95% CI 2.90-10.35), and 3 or more adenomas (aHR 2.61, 95% CI 1.46-4.69) at the follow-up colonoscopy examination. CONCLUSION: Insulin therapy is associated with an increased risk of advanced adenoma and may serve as a novel risk-stratification factor to enhance the efficiency of existing colorectal cancer screening and surveillance programs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Section of Digestive Diseases, Yale School of Medicine, New Haven, CT, USA.
- Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, 19104, USA.
- Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
- Mount Sinai School of Medicine, New York, NY, USA.
- Tel-Aviv University, Tel-Aviv, Israel.
- Department of Oncology, Sheba Medical Center, Tel-Hashomer, Ramat Gan, Israel.
Förderung
- CSRD VA
- U.S. Department of Veterans Affairs
Zitieren
APA
Lam, R., Hwang, W. T., Chennareddy, S., Boursi, B., & Yang, Y. X. (2024). Exogenous Insulin Therapy Is Associated with the Risk of Advanced Colorectal Adenoma in Patients with Diabetes Mellitus. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-024-08350-8
Vancouver
Lam R, Hwang WT, Chennareddy S, Boursi B, Yang YX. Exogenous Insulin Therapy Is Associated with the Risk of Advanced Colorectal Adenoma in Patients with Diabetes Mellitus. Digestive Diseases and Sciences. 2024. doi:10.1007/s10620-024-08350-8
BibTeX
@article{Lam2024,
author = {Lam, Robert and Hwang, Wei-Ting and Chennareddy, Sumanth and Boursi, Ben and Yang, Yu-Xiao},
title = {Exogenous Insulin Therapy Is Associated with the Risk of Advanced Colorectal Adenoma in Patients with Diabetes Mellitus},
journal = {Digestive Diseases and Sciences},
year = {2024},
doi = {10.1007/s10620-024-08350-8}
}
EUVIMED